One breast cancer survivor isn't into pink

The color pink has become almost inextricably associated with breast cancer research, especially during October. For many people, wearing pink clothes or using pink products can feel like a way to morally support friends and family who have had the disease while also monetarily contribute to research that could find ways to save lives.

But as a breast cancer survivor wrote in the Houston Chronicle, some people have “mixed feelings” about the October ubiquity of pink.

Shelly Reese Bain wrote about her feelings of “pinkwashing”—using the color pink to market products to people who use the retail activism to justify their purchases.

“Before I had breast cancer, I was certainly guilty of using pink ribbons to justify my purchases: ‘This plastic water bottle is really cute, plus it benefits people with breast cancer!’ Turns out, that plastic bottle probably contained phthalates, a dangerous chemical used in products ranging from plastic bottles to vinyl flooring to body lotion,” Reese Bain said.

Some chemicals such as phthalates could be among the very culprits that cause cancer in the first place. The author also found unhealthy foods wrapped in pink to be “ironic” and “infuriating,” since a surgery diet is also known to increase the risk of cancer.

Plus, how do consumers know if these pink-laden products’ manufacturers actually donate to breast cancer support organizations?

Instead of buying into “cutesy” marketing campaigns, the author says, instead try donating directly to organizations that fight breast cancer.  

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Around the web

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.